Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Phase 2 Completed
68 enrolled 13 charts
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
Phase 2 Completed
29 enrolled 15 charts
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Phase 2 Completed
4 enrolled 10 charts
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
Phase 2 Completed
70 enrolled
MK-3543-004
Phase 2 Completed
20 enrolled
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
Phase 2 Completed
31 enrolled 8 charts
Pegasys® in Patients With Myeloproliferative Diseases
Phase 2 Completed
83 enrolled 12 charts
Low-PV
Phase 2 Completed
127 enrolled
AIRPORT-MPN
Phase 2 Completed
44 enrolled
PACIFIC
Phase 2 Completed
20 enrolled
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Phase 2 Completed
50 enrolled 11 charts
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Phase 2 Completed
40 enrolled
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Phase 2 Completed
117 enrolled 27 charts
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
Phase 2 Completed
125 enrolled 38 charts
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
Phase 2 Completed
10 enrolled 7 charts
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Phase 2 Completed
77 enrolled 16 charts
Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
Phase 2 Completed
29 enrolled 8 charts
PV
Phase 2 Completed
45 enrolled 10 charts
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
94 enrolled 11 charts
Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
Phase 2 Completed
25 enrolled 8 charts
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
Phase 2 Completed
18 enrolled
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Phase 2 Completed
135 enrolled
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Phase 2 Completed
204 enrolled 7 charts
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
Phase 2 Completed
455 enrolled
ET/PV
Phase 2 Completed
20 enrolled
Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
Phase 2 Completed
40 enrolled
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Phase 2 Completed
39 enrolled
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
Phase 2 Completed
210 enrolled 10 charts
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Phase 2 Completed
35 enrolled 8 charts
Effects of Imatinib Mesylate in Polycythemia Vera
Phase 2 Completed
9 enrolled
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
Phase 2 Completed
48 enrolled 7 charts
Imatinib Mesylate in Treating Patients With Myelofibrosis
Phase 2 Completed
18 enrolled
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
Phase 2 Completed
35 enrolled
Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
Phase 2 Completed
72 enrolled
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
Phase 2 Completed
171 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
Phase 2 Completed
37 enrolled
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
Phase 2 Completed
58 enrolled
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
Phase 2 Completed
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis
Phase 2 Completed
Treatment of Polycythemia Vera With Gleevec
Phase 2 Completed
36 enrolled
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Phase 2 Completed